At this rate, before long the drug industry may not include any major firms that manufacture products marketed on both sides of the Rx and OTC divide.
With its announcement on 12 November to separate its consumer health business as a standalone, publicly traded company within two years, Johnson & Johnson is taking the same approach that GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?